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Background: Data of the Central Bureau of Statistic of Nepal from 2008 show a total of more than 46,000
illegal drug users, out of which 61% are injecting drug users (IDU). An injecting mix of medicines like opioids,
benzodiazepines and antihistamines (the so-called South Asian cocktail) was prevalent. Furthermore, it is estimated
that about 70,000 people are living with human immunodeficiency virus (HIV). The government of Nepal has started
realizing and recognizing drug use and HIV as significant health and social issues. Harm reduction programs such
as needle syringe exchange and opioid substitution treatment are being implemented.
Methods: The aim of this study is to obtain specific knowledge on the drug use behaviour and the health status
of drug users with a focus on HIV in drug users with concurrent injection of opioids, benzodiazepines and
antihistamines. After an initial mapping of Kathmandu Valley, 300 drug users in contact with different treatment
and counselling centres were randomly chosen for the interviews. The research questionnaire was designed
according to the European Addiction Severity Index (EuropASI) and Maudsley Addiction Profile standards.
Results: Ninety-one percent of the respondents are male and 9% female. Mean age is 28.7 years. Ninety-five
percent are injecting drug users with a mean of 8.7 years of drug use history. Eighty-six percent are injecting
different ‘cocktails’, usually made of buprenorphine, diazepam, promethazine and/or other substances (30-day
prevalence). Similarly, 48% use heroin, whereas only 2% take cocaine/crack. Among those tested for HIV (N = 223),
33% are positive (25% of the sample population). Compared to the other drug users (mainly heroin), the cocktail
users show a higher HIV infection rate and more co-infections. Furthermore, risk behaviour, as e.g. needle sharing,
is much more common among the cocktail users.
Conclusion: Currently, the mixture of medicines, opioids, benzodiazepines and antihistamines, is the predominant
drug in Nepal; the pharmaceutical drugs needed to prepare the cocktail are less expensive than heroin and
relatively easy to acquire. The cocktail users show a higher risk behaviour regarding the transmission of HIV than
heroin drug users. It needs to be considered which HIV prevention measures are necessary to target the specific
needs of drug users who inject a mixture of opioids, benzodiazepines and antihistamines, since the available
services (such as needle syringe exchange) do not seem to cover their specific needs (high percentage of
needle sharing).
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People who use drugs are at risk of getting infected with
human immunodeficiency virus (HIV) and of transmit-
ting the infection to other drug users via needle-syringe
sharing or to their sex partners through unsafe sex.
Injecting drug users can act as a bridge to transmit HIV
to others with whom they have sexual contacts. According
to the Integrated Biological and Behavioral Surveillance
(IBBS) report 2011, 76% of injecting drug users (IDUs) in
Kathmandu Valley consistently used condoms with female
sex workers, while 40% used condoms consistently with
non-regular sex partners and only 9% used condoms con-
sistently with regular female sex partners in the past year
[1]. Numerous studies have found IDUs to be dispropor-
tionately likely to be involved in unsafe sex practices [2,3].
Sex workers (male and female), who offer sex in exchange
for money or drugs, are at high risk for HIV infection and
can spread the virus to a large number of people. In
addition, sexual contact between IDUs and non-injectors
may also contribute to an increased incidence of HIV
infection. Furthermore, HIV transmission to children by
drug-injecting mothers (‘vertical transmission’) or by non-
injecting mothers in partnership with IDUs is pervasive.
As a result of high-risk sexual behaviour, HIV is also a risk
among drug abusers who do not inject drugs.
Until the 1990s, injecting drug use was rare in Nepal.
With the introduction of pharmaceutical drugs such as
buprenorphine, benzodiazepines, chlorpromazine and
dextropropoxyphene, a transition took place, away from
smoking or chasing heroin and towards injecting drug
mixtures, mainly of buprenorphine mixed with benzodi-
azepines and chlorpromazine, as well as other antihista-
mines—the so-called South Asian cocktail. Polydrug use
appeared to be the norm (ranging from alcohol to heroin),
and transition from non-injecting to injecting behaviour
appeared to be linked to the need for choosing the most
cost-effective route of administration [4].
As per the study conducted by the Central Bureau of
Statistic (CBS) of Nepal, more than 46,310 people are
using illicit, ‘hard’ drugs such as opiates, cocaine or
amphetamines in Nepal [5]. Most of them are male
(92.8%); only 7.2% are women. A major share of this num-
ber, i.e. 61.4%, is constituted by injecting drug users. It is
estimated that in Nepal, 70,256 people are living with HIV
[6]. A substantial proportion of IDUs are HIV-infected.
However, in the metropolis region of Kathmandu, the
prevalence of HIV infections among IDUs has decreased
from 51.7% in 2005 to 20.7% in 2009 [7]. According to the
IBBS 2011 report, HIV prevalence was found in 16.3% of
IDUs who had been injecting drugs for more than 5 years,
while no HIV infections were found among those who
had injected for less than 1 year [1].
The impact of many types of psychoactive substances,
including alcohol, and regardless of the fact whether theyare injected or not is risky to the extent that they are dis-
inhibitors and affect the individual's ability to make deci-
sions about safe sexual behaviour. In this context, the
non-governmental organization ‘Recovering Nepal’ has
found, according to its study from 2009, that IDUs are
using multiple drugs as a mixture of injectable substances
in order to achieve a stronger effect [8]. This is also sup-
ported by the IBBS 2011 report which states that IDUs in
Kathmandu Valley mostly used a combination of drugs. In
fact, about 89% of the IDUs used different combinations
of drugs [1]. According to Larance and colleagues, bupre-
norphine has reportedly emerged as the favoured drug of
injection among IDUs [9]. Also, in India, an increase in
the consumption of prescription opioids such as bupre-
norphine, codeine and dextropropoxyphene among drug
users has been observed in the past decade [10]. This so-
called cocktail use behaviour has created health, social,
economic and legal hazards to IDUs.
The coverage of opioid substitution treatment (OST)
in Nepal is comparatively low, and high-risk injecting
and sexual behaviour among IDUs continues. The finan-
cing of OST is largely provided by external donors, and
donations have become scarce with the current global
economic problems [11].
This study was conducted in order to understand the
current situation of illegal drug use with a special focus on
concurrent injection of a mixture of opioids, benzodiaze-
pines and antihistamines in Nepal and to gain knowledge
on the use of such ‘drug cocktails’ and its hazards in IDUs.
In particular, this study aimed at identifying possible dif-
ferences between drug users with and without concurrent
consumption of opioids, benzodiazepines and/or antihis-
tamines with respect to their living situation, health status,
drug use history, different types of combinations of drugs,
risk behaviour, causes and motives of consumption as well




A cross-sectional survey among opiate users in contact
with the treatment system was conducted. As per the CBS
study [5], in 2008, around 17,458 drug users resided in the
Kathmandu Valley (Kathmandu, Lalitpur and Bhaktapur).
As the research focuses especially on concurrent use of
opioids, benzodiazepines and antihistamines, Kathmandu
Valley was selected for this survey due to its high
concentration of illegal and opiate drug users, includ-
ing injecting drug users. Out of the 17,000 plus opiate
drug users in Kathmandu Valley, 300 IDUs were selected
for this study.
Beforehand, a mapping of the institutions/services and
the number of patients in treatment in Kathmandu Valley
had been carried out in order to calculate the sample size.
Ojha et al. Harm Reduction Journal 2014, 11:17 Page 3 of 8
http://www.harmreductionjournal.com/content/11/1/17The sample should consist of about 20% of the target
group, but not more than 300 persons.
Patients were randomly chosen from the lists of the
respective treatment facilities. If a person refused to
take part in the interview the next patient on the list
was asked to participate. Altogether 300 drug users
(IDUs) were interviewed for this study. The sample
size was determined by the expedience method, thereby
including those items readily available or convenient
to collect.
As the research focuses on illegal drug users, only
persons in contact with rehabilitation centres, treatment
centres, OST clinics and counselling services were inclu-
ded in the study. Centres from Kathmandu, Lalitpur and
Bhaktapur were visited to collect information.
Face-to-face interviews
Six trained interviewers conducted structured inter-
views with the participants. After piloting with five
respondents, only slight changes were made to the
questionnaire. Prior to the study, the interviewers received
special training on the content of the interview, the orga-
nization of the centres and how to communicate with the
drug users.
The interviewers used a questionnaire designed ac-
cording to standards of the European Addiction Severity
Index (EuropASI) [12] and the Maudsley Addiction Profile
(MAP) [13] in order to provide comparability with other
international studies.
The interviewers requested information on patients'
socioeconomic characteristics (age, gender, years of
education, marital status and job status), addiction
history prior to treatment entry: all drugs used for at
least 1 month in their lives, routes of administration,
the main drug of abuse (the most problematic drug, i.e.
main cause for treatment entry), age at first drug
abuse, the duration of drug use and the total amount
of money spent on drugs in the most recent month
of abuse. In addition, the interviewers also inquired
about the patients' ‘cocktail’ drug use history: types of
combinations and medicines, history, causes of cock-
tail use, routes of administration, sources of syringes,
cost of drugs, etc.
The interviewers conducted the interviews in cooper-
ation with the staff of the centres who encouraged the
selected patients to participate. Patients usually spent
some time in the waiting room before visiting the
counsellor, receiving their medication or visiting their
doctor, thus providing a good opportunity for the inter-
view. The interviewers explained the study to the drug
users individually and inquired about their willingness to
participate. The data collection in each facility or clinic
was continued in order to reach all patients that visited
the institution within 1 month.Ethical approval
The data collection was carried out using an anonymous
patient characteristic form which aimed at providing as
much confidentiality as possible. The study was volun-
tary, and all respondents provided their written informed
consent. The National Health Research Council of Nepal
approved the study.
Statistical analysis
With respect to the consumption of drug mixtures, the
study participants were divided into three groups. The
category ‘intensive use’ is used for persons who took at
least two different kinds of cocktails and at least one of
them on a daily basis. The ‘moderate users’ consumed
the combination of opioids, benzodiazepines and/or an-
tihistamines on at least 1 day (or more) in the past
month without fulfilling the above-mentioned criteria.
The ‘non-cocktail users’ did not use these drug combina-
tions during the past 30 days.
The data were transferred from the paper forms to a
digital format. Statistical data analysis was performed
using the Statistical Package for the Social Sciences
(SPSS for Windows, version 19 [14]), and any differences
in frequencies were analysed using the chi-square test;
the ANOVA and t test served to compare the means
(level of significance p < .05).
Results
Sample characteristics
Ninety-one percent of the respondents are male and 9%
female. Mean age is 28.7 years (range 17 to 51 years);
more than half of the drug users are between 26 and
35 years old. The majority is currently in in- or out-
patient rehabilitation (together 43%); about one fifth is
treated with methadone or buprenorphine. One tenth of
the drug users are in contact with drop-in centres. Be-
fore entering treatment, almost all respondents had a
stable living situation (98%); only 2% lived in hotels or in
institutions or were homeless. Two thirds lived in a
stable relationship, whereas almost half of this group
(in total 32%) had partners with addiction problems
of their own. Almost one third reached high school
level; 43% finished secondary school. The majority of
drug users were working or in training before enter-
ing treatment; only one third was unemployed. Two
thirds of the sample have been charged for criminal
offences at least once in their life (68%); 87% have been in-
carcerated or imprisoned. During the past 30 days before
treatment, 62% have been involved in criminal activities.
Health status
Forty-seven percent of the Nepali drug users have been
hospitalized for medical problems at least once, and 39%
suffer from chronic health problems. Among tested drug
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sample). Fifty-nine percent of the study participants
tested for hepatitis C (N = 149) are infected (29% of the
whole sample). Eighty-three percent of HIV-positive
drug users have co-infections of hepatitis C. In the past
12 months before entering treatment, 43% suffered from
abscesses or skin infections.
Among male drug users, 36% are HIV positive; in
women, this is true for only one person (4.5%). The mean
score of physical health problems according to MAP
(range 0–4) is 1.4 for the HIV-positive respondents
and 1.3 for the persons without HIV infection (t = 1.18,
p = .238). The MAP mental health score is significantly
higher among respondents with HIV infection (2.2) than
among those without (1.8) (t = 4.5, p < .001). Almost one
quarter has attempted suicide at least once before in their
life (23%), and one third has experienced drug overdoses
in their life before entering treatment.
Drug use history
The majority (95%) are injecting drug users with a mean
of 8.7 years of drug use history. Eighty-six percent of the
sample were injecting different mixtures of drugs usually
made of buprenorphine, diazepam, promethazine and/or
other substances (30-day prevalence before entering
treatment). Almost half of the sample used heroin (48%),
whereas only 2% took cocaine or crack. Cannabis is the
most frequently consumed illegal drug among the drug
users of Kathmandu Valley. Risk behaviour is very com-
mon, i.e. 53% have shared needles and/or syringes, and
two thirds have shared other equipment for intravenous
use in the past 12 months before entering treatment.
According to the number of different kinds of drug
mixtures and the frequency of use, 52% are intensive
consumers of the so-called South Asian cocktail. Thirty-
four percent take those mixtures of drugs on a moderate
(less frequent) basis (see below). Fourteen percent of the
drug users did not consume opioids in combination with
benzodiazepines and antihistamines and/or other drugs
in the last month.
Differences between sample characteristics regarding
the intensity of concurrent drug use are shown in
Table 1. First of all, a significantly higher proportion of
men can be found among the users of drug mixtures.
The intensive cocktail users are significantly older than
the moderate users and have an overall lower level of
education compared to the persons without concurrent
use of opioids, benzodiazepines and antihistamines and/
or other drugs. Intravenous drug use, at least once in
life, was found in all cocktail users, i.e. 100% compared
to two thirds among the other group. There is also a
significantly higher proportion of intensive and moderate
drug users who have serious health problems in compari-
son to the persons without concurrent use of opioids,benzodiazepines and antihistamines and/or other drugs.
With respect to co-infections, the prevalence is signifi-
cantly higher among intensive cocktail users, compared to
both other groups of drug users. Similarly, the prevalence
of mental health problems is also significantly higher
among intensive users of mixed drugs.
Different types of combinations of drugs
As mentioned above, 86% of the sample population use
opioids in combination with benzodiazepines and anti-
histamines or other substances, i.e. they use it to mix
specific cocktails. Forty-five percent of the drug users
took three or four different cocktails in the past 30 days.
According to the results of the interviews and res-
pondents' statements, the following different types of
substance mixtures are consumed by the drug users in
Kathmandu Valley. Only 12% of the men and 39% of the
women did not use mixed drugs in the past 30 days
before the interview (Table 2). On the other hand, it can
be shown that different types of substance combinations
are used by the same person. The mean number of dif-
ferent cocktails used is 2.0 (±1.3). Based on the persons
with concurrent use of different drugs only, the mean
number is 2.4 (±1.0). Except for five (male) persons who
took cocktail 4 (‘other’) orally, all kinds of cocktails were
consumed intravenously.
Concurrent drug use and risk behaviour
Different kinds of cocktails are usually consumed several
times a day. The majority of intensive users normally
take (any kind of ) drug mixture three or more times a
day (70%). This is also true for the moderate users (69%).
Another quarter of both groups consume opioids in com-
bination with different other drugs twice on a typical day
(intensive users 26%; moderate users 25%).
As already mentioned above, 52% of the drug users are
intensive consumers of combinations of drugs. Empiric-
ally, the mean number of different cocktails consumed in
this group is 3.0 (±0.6). Thirty-four percent take opioids in
combination with other drugs on a moderate (less fre-
quent) basis. Their mean number of cocktails used during
the past 30 days is 1.5 (±0.8).
Data on drug use and risk behaviour during the past
30 days was collected from the respondents. Table 3
gives us a picture of the situation. As expected, the
percentage of heroin users is the highest in the group
without concurrent use of opioids, benzodiazepines and
antihistamines and/or other drugs. However, heroin use
among intensive cocktail users is significantly higher
than in moderate users. Cannabis is more commonly
consumed among the groups with combined drug use,
whereas only the difference between non-cocktail users
and moderate users reached statistical significance. Table 3
reveals that chewing tobacco is also a highly used drug
Table 1 Sample characteristics and drug use history of the drug users in Kathmandu Valley (N = 300)
No cocktail use Moderate use Intensive use Significancea (χ2, ANOVA)
Gender 74.4% x, y 91.2% x 94.8% y χ2 = 16.6, p < .001
Age, years 28.1 (±6.7) 27.6 (±6.2) z 29.6 (±6.1) z F = 3.5, p < .05
Currently in OST 18.6% 20.6% 21.3% χ2 = 0.1, p = .928
Education level
Primary schoolb 18.6% y 23.5% 32.9% y χ2 = 12.4, p < .05
Secondary school 32.6% y 48.0% 43.2% y
High school 48.8% y 28.4% 23.9% y
Stable living situation 100.0% 96.1% 98.7% χ2 = 3.2, p = .202
Employment
Working/student 60.5% 56.9% 57.4% χ2 = 2.8, p = .593
Unemployed 25.6% 36.3% 32.9%
Household/other 14.0% 6.9% 9.7%
Ever injected drugs 67.4% x, y 100.0% x 100.0% y χ2 = 87.8, p < .001
Length of injecting drug use, years 8.5 (±6.6) 8.4 (±5.5) 10.1 (±6.1) F = 2.9, p = .057
Length of cocktail use, yearsc 7.8 (±6.5) 8.0 (±5.0) 9.2 (±5.6) F = 1.7, p = .191
Length of heroin use, years 9.9 (±6.0) 11.0 (±6.3) 12.2 (±6.2) F = 2.4, p = .090
Serious health problems 4.7% x, y 20.6% x 23.2% y χ2 = 7.4, p < .05
HIV positive (among tested) 26.9% 24.2% 38.5% χ2 = 4.5, p = .108
HCV positive (among tested) 38.9% 58.3% 63.9% χ2 = 3.8, p = .147
Co-infection 18.6% y 31.4% z 47.7% y, z χ2 = 15.0, p < .001
Physical health (MAP score, 0–4) 1.4 (±0.4) 1.4 (±0.4) 1.3 (±0.5) F = 1.5, p = .217
Mental health (MAP score, 0–4) 1.7 (±0.7) 1.7 (±0.7) z 2.0 (±0.8) z F = 4.6, p < .05
N 43 102 155
aThe characters x, y and z indicate significant differences between groups according to post hoc statistical tests. bPrimary school or lower. cIn the group without
cocktail use, the number of years is related to former periods of concurrent use of opioids, benzodiazepines and antihistamines and/or other drugs.
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intensive users also consume a broader range of sub-
stances than the group without concurrent use of opioids
and/or other drugs.
With respect to risk behaviour, the study shows that
because needle sharing is significantly more common
among intensive cocktail users, they are at a higher risk
than moderate users and non-users. Similarly, intensive
users also share other equipment very frequently. In
both groups of users of mixed drugs, higher percentages
of persons than in the non-user group use the sameTable 2 Different types of polydrug injection on a single occa
Type of drug combinationa
1. Buprenorphine + diazepam
2. Buprenorphine + diazepam + promethazine
3. Buprenorphine + diazepam + promethazine + other antihistamine
4. Other (buprenorphine + promethazine or cocktail + pheniramine maleate)
No cocktail use
Mean number of cocktails (±SD)
aThe first three kinds of drug mixtures were consumed intravenously only; cocktailneedle several times. In summary, it can be stated that
especially intensive users of opioids in combination with
other drugs practice risk behaviours significantly more
often than the remaining groups.
Most of the intensive cocktail users feel that the
concurrent use of these substances alleviates mental symp-
toms such as depressive feelings or anxiety (59%; moderate
users 40%). Much more intensive cocktail users (45%) than
moderate users (25%) consume opioids in combination
with other substances because the drug (mixture) helps
to handle their situation or to ease personal problems.sion of use consumed by drug users (N = 300)
Men Women Total Significance (χ2, t test)
64.7% 53.6% 63.7% χ2 = 3.2, p = .243
59.2% 46.4% 58.0% χ2 = 1.7, p = .193
69.5% 42.9% 67.0% χ2 = 8.1, p < .01
15.8% 7.1% 15.0% χ2 = 1.5, p = .221
11.8% 39.3% 14.3% χ2 = 15.7, p < .001
2.1 (±1.2) 1.5 (±1.5) 2.0 (±1.3) t = 2.0, p < .05
number 4 (other) was taken orally by five (male) persons.
Table 3 Drug use (past 30 days) and risk behaviour of the drug users in Kathmandu Valley (N = 300)
No cocktail use Moderate use Intensive use Significancea (χ2, ANOVA)
Alcohol 66.7% 66.7% 60.6% χ2 = 1.2, p = .558
Number of days 19.1 (±11.7) 22.1 (±10.0) 18.6 (±10.4) F = 2.4, p = .098
Heroin 81.4% x, y 29.4% x, z 51.0% y, z χ2 = 33.9, p < .001
Number of days 27.0 (±7.4) x, y 13.8 (±10.6) x 16.0 (±10.2) y F = 19.5, p < .001
Cannabis 69.8% x 87.3% x 80.0% χ2 = 6.2, p < .05
Number of days 24.8 (±9.1) 21.7 (±9.6) 24.0 (±8.1) F = 2.5, p = .088
Benzodiazepines 27.9% x, y 94.1% x 89.7% y χ2 = 103.1, p < .001
Number of days 22.6 (±9.4) 25.0 (±8.8) 26.2 (±6.8) F = 1.7, p = .193
Chewing tobacco 25.6% y 39.2% z 52.3% y, z χ2 = 11.2, p < .01
Number of days 23.5 (±9.1) 24.5 (±9.1) 21.3 (±9.9) F = 1.5, p = .229
Number of different substances 4.7 (±1.8) x, y 6.0 (±1.5) x 6.5 (±1.9) y F = 17.7, p < .001
Use of 10-ml syringes 11.8% x, y 61.8% x 56.9% y χ2 = 14.9, p < .001
Multiple use of the same needle 45.0% x, y 69.6% x 74.8 y χ2 = 13.3, p < .01
Needle/equipment sharing 48.8% y 61.8% z 90.3% y, z χ2 = 43.8, p < .001
N 43 102 155
aThe characters x, y and z indicate significant differences between groups according to post hoc statistical tests.
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intensive cocktail users (28%; moderate users 18%)
stated to use a mixture of opioids, benzodiazepines and/
or antihistamines because they are cheaper than other
drugs.
For the intake of these drug cocktails, all drug users
use syringes. Most of the drug users generally obtain
syringes from pharmacies or drug stores (intensive
users 98%; moderate users 100%). A lower proportion
of the respondents receive syringes from needle exchange
programs in different parts of Kathmandu (intensive users
70%; moderate users 75%). The substances contained in
the cocktails are obtained from different sources. The
main sources of these substances are drug dealers (inten-
sive users 94%; moderate users 89%) and pharmacies
(intensive users 72%; moderate users 80%).Table 4 Drug use history and risk behaviour of the interviewe
HIV positive
Age, years 33.1 (±6.0)
Length of injecting drug use, years 14.2 (±5.7)
Length of cocktail use, years 12.8 (±5.6)




Multiple use of the same needle 91.9%
Needle/equipment sharing 93.2%Drug use and risk behaviour by HIV status
Differences in drug use and risk behaviour become appar-
ent when persons with and without HIV infection are
compared (Table 4). The HIV-positive drug users are
about 5 years older on average and, correspondingly, have
a longer ‘addiction career’ than the HIV-negative persons.
Although not statistically significant, there is a tendency
for combined use of opioids, benzodiazepines and/or anti-
histamines to be more prevalent in HIV-positive persons
(see also Table 1). Furthermore, a strong association be-
tween HIV status and risk behaviour can be shown.
Discussion and conclusion
This survey among 300 drug users of Kathmandu Valley is
the first systematic study to shed a light on the current
living situation, the state of health and drug use, as well asd drug users in Kathmandu Valley (N = 223)
HIV negative Significance (χ2, t test)
28.2 (±5.6) t = 6.0, p < .001
8.5 (±5.3) t = 7.3, p < .001
7.8 (±4.5) t = 6.9, p < .001
10.5 (±5.0) t = 6.9, p < .001
31.5% χ2 = 4.5, p = .108
55.7%
63.5% χ2 = 20.1, p < .001
75.2% χ2 = 10.6, p < .01
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of opioids, benzodiazepines, antihistamines and/or other
substances who are in contact with addiction services in
Nepal. It provides current and specific knowledge on the
status of HIV and other infections.
At present, the so-called South Asian cocktail, usually
a combination of opioids, benzodiazepines and/or anti-
histamines, is the predominant drug in Nepal. The
pharmaceutical drugs needed to prepare the mixture are
less expensive than heroin and relatively easy to acquire.
The drug users who consume opioids in combination
with other medical substances have a higher risk behav-
iour than heroin drug users which is associated with the
spread of HIV. It needs to be considered which HIV pre-
vention measures are needed related to the specific
needs of the so-called cocktail users, since the available
services (such as needle syringe exchange) do not seem
to cover their specific needs (high percentage of needle
sharing). Respectively, it is necessary to identify why the
available HIV prevention services (e.g. needle syringe ex-
change) do not cover the specific needs of drug addicts
with combined drug use. Furthermore, OST services
should be extended to decrease intravenous drug use
effectively and to prevent infections of HIV, hepatitis
and tuberculosis among IDUs. The level of OST cover-
age in Nepal is relatively low. As presented in the
systematic review by Mathers et al. [15], the number of
OST recipients in South Asia is 15 to 25 per 100 IDUs.
Although the number of OST clinics increased from
three to five in 2013 with a maximum number of 750
treatment slots, the coverage is still only about 2.5% of
the intravenous drug users in Nepal.
With the normal pattern of consumption being to use
these cocktails several times a day and the main reason
for consumption being to alleviate psychological symp-
toms, this leads to the question whether users of drug
mixtures practice a kind of self-medication of underlying
mental symptoms or a kind of self-substitution of with-
drawal symptoms, rather than using drugs in order to
reach a ‘high’ or specific feelings. Especially diazepam
has a long half-life period which produces a cumulative
effect in the body. Thus, specific consequences and side
effects of benzodiazepine dependence will arise after
long-term concurrent use of opioids in combination
with benzodiazepines and/or antihistamines. This indi-
cates a much higher need for a comprehensive treatment
approach in the region which provides the opportunity to
offer appropriate treatment for other mental and somatic
symptoms.
This study is the first of its kind to understand the
situation of the so-called cocktail drug use in Nepal, and
its results have shed some light on the circumstances of
this special kind of combined drug use. At the same
time, this research has detected the following morespecific research needs: What is the specific situation of
cocktail drug users with HIV infection? And how are
other health needs of drug users who consume opioids
in combination with benzodiazepines and/or antihista-
mines addressed, especially psychiatric co-morbidity?
Furthermore, the specific role and effect (and possible
risks) of the antihistamine within the mixture of sub-
stances has to be investigated.
Research also reveals that the substances for the drug
mixture are catered by drug stores and chemists. This
indicates a significant need for awareness raising among
drugstore keepers, in order for them to understand the
consequences of selling these drugs without a proper
prescription.
With respect to harm reduction services and treat-
ment offers, the question arises to what extent cocktail
drug users utilize and benefit from harm reduction pro-
grammes. Furthermore, as buprenorphine is found to be
the main substance involved in intravenous abuse of
mixed drugs in Nepal, a need for scaling up buprenor-
phine substitution treatment within the OST program in
Nepal has to be considered.
One limitation of our study is the choice of the sample
which only consists of persons who are in contact with
drug services or treatment. Thus, no information on
drug users without professional support can be obtained,
and we do not know how much we can extend these
findings to the other substance users in Nepal. This
would be of particular interest, as the majority of drug
users in Nepal are not reached by special services. Thus,
a national level survey is needed to understand the situ-
ation of drug users who consume opioids in combination
with benzodiazepines and/or antihistamines in Nepal.
However, the specific problems of persons with concur-
rent use of opioids in combination with benzodiazepines,
antihistamines and/or other substances should be covered
by professional services which, again, require an increase
in capacity of OST and harm reduction activities for drug
users.
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